Web Design for Pharmaceutical Companies: A 2026 UK Guide

Pharma web design is the only branch of web design where the wrong sentence on a page can trigger a regulatory complaint. Everything else follows from that.

Why Pharma Web Design Is a Different Discipline

Most website projects optimise for one thing: getting the visitor to act. Pharmaceutical web design optimises for two things simultaneously, and they pull against each other. You need the site to communicate clearly and persuasively, and you need every claim on it to survive scrutiny from the Medicines and Healthcare products Regulatory Agency and, for most companies operating in the UK, from the industry's own code of practice, the 2024 ABPI Code, in full force since 1 January 2025.

That constraint reaches further into the build than people expect. It is not a compliance review bolted onto the end. It changes the information architecture (because patient and healthcare professional content must be separated), the content model (because every claim needs a traceable reference), the publishing workflow (because sign-off has to be recorded), and even the component library (because a testimonial carousel or a "results in 7 days" badge that is fine for a consumer brand may be unusable for you).

The commercial consequence is that pharmaceutical websites tend to be either badly over-lawyered, to the point of being useless to the people they are meant to serve, or dangerously casual, built by an agency that treated it as a normal corporate site. Good web design for pharmaceutical companies treats the regulatory boundary as a design input from day one, which is genuinely easier than retrofitting it, and considerably cheaper than a rebuild after a complaint is upheld.

Six Pillars of Effective Pharmaceutical Web Design

Build for the MHRA and the ABPI Code From the Start

UK medicines advertising is governed by the Human Medicines Regulations 2012 and, for member companies, by the 2024 ABPI Code of Practice administered by the PMCPA. The single rule that shapes site structure most is that prescription-only medicines cannot be advertised to the general public. Decide early which audiences each section serves, and build the access controls before you write the copy, not after.

Treat Accessibility as a Legal Baseline

Your users include people with impaired vision, tremor, cognitive fatigue, and low health literacy, often because of the conditions your products treat. Target WCAG 2.2 AA as a minimum: proper heading order, keyboard operability, 4.5:1 contrast, visible focus states, and forms that announce their errors. Accessibility overlays are not a substitute and are widely regarded as a liability rather than a fix.

Separate Patient and Healthcare Professional Journeys

Promotional content about prescription-only medicines must either be restricted to healthcare professionals or sit in a clearly separated section with the intended audience identified, which is what the Code's supplementary information on website access requires. The common pattern is an interstitial that asks the visitor to confirm they are a UK healthcare professional, and it needs to be a genuine decision point that covers every page and file in the section, not a dismissible banner. Keep the two content sets on distinct URL paths, so search engines, analytics and your own reviewers can tell them apart at a glance.

Earn Trust With Transparency and Evidence

Every efficacy or safety claim needs a visible, dated reference. Publish author credentials, medical review dates, and the summary of product characteristics where relevant. This is a compliance requirement, but it is also the single biggest driver of perceived credibility for prescribers and journalists, both of whom check.

Protect Data and Lock Down Security

Adverse event forms, patient support sign-ups, and HCP registrations collect special category data under UK GDPR. That means a lawful basis, a data protection impact assessment, encryption in transit and at rest, minimal retention, and a hosting arrangement you can actually evidence. Assume you will be asked to prove all of it.

Structure Content for Search and Comprehension

Regulated copy is dense by necessity, which makes structure the main lever you have left. Short sections, descriptive headings, plain-English summaries above technical detail, and a glossary for the terms you cannot avoid. Structured data helps machines parse the page without you having to soften the clinical language.

POM, OTC and Unbranded: Three Site Types, Three Rule Sets

Most confusion in pharma web design comes from treating "the website" as a single thing. In practice a UK pharmaceutical company usually operates three distinct types of web property, and the rules differ sharply between them.

• Prescription-only medicine (POM) sites. These cannot be promoted to the public at all. Under the supplementary information to clause 16.1 of the ABPI Code, promotional material either has to be limited to health professionals and other relevant decision makers, or the site has to carry separate, clearly labelled sections for the public and for professionals. The usual approach is to put branded content behind a self-certification gate. The public side is limited to non-promotional information, and clause 26 describes the reference information companies can publish, calling it good practice to include at least the summary of product characteristics, the patient information leaflet and the public assessment report where one exists. Get this wrong and you are not making a marketing mistake, you are making a regulatory one.
• Over-the-counter and pharmacy medicine sites. These can be advertised to the public, but the advertising must comply with the rules in Part 14 of the Human Medicines Regulations 2012. The MHRA's guidance on advertising medicines lists what a public advert must include: the product name, the active ingredient if there is only one, what the medicine is for, an instruction to always read the label or leaflet and, for products only available in Great Britain, a statement that the product is not available, or not available without a prescription, in Northern Ireland. It must not suggest the medicine has no side effects or that its effects are guaranteed. The design challenge is fitting that information into a product page that still converts, so build it into the template rather than leaving it to each page.
• Unbranded disease-awareness sites. These educate about a condition without naming a product. They are a legitimate and widely used route to reach patients on POM-treated conditions, but the line between education and disguised promotion is exactly where complaints are made. Keep the product entirely absent, keep the clinical information balanced across treatment options, and document the editorial process.

Deciding which of the three you are building, before wireframes, removes most of the downstream argument. Companies that skip this step end up with one site trying to serve all three purposes, which satisfies none of them and is very difficult to defend.

Pharmacy Websites Are a Different Brief

Search results for pharma web development are crowded with agencies that build websites for community pharmacies, which is a related but separate job. A pharmacy site is mostly retail and services: it sells pharmacy and general sale medicines, books consultations and takes prescription orders, and pharmacies answer to a pharmacy regulator (the General Pharmaceutical Council in Great Britain) rather than to the PMCPA. One rule catches teams that move between the two. Online sellers based in Great Britain have not had to display the Distance Selling Logo since 1 January 2021, but sellers in Northern Ireland must still register with the MHRA and show the logo on every page that offers medicines for sale. This guide is written for manufacturers, licence holders and life sciences companies. If you run a pharmacy, the build priorities are ecommerce and booking rather than HCP gating.

Pharmaceutical Research, Biotech and Life Sciences Websites

Not every organisation in this space markets a medicine. Contract research organisations, biotech firms pre-approval, diagnostics companies, and pharmaceutical research groups have a different problem: they are not advertising to patients at all, they are selling credibility to investors, partners, and recruiters.

In fact most of the sector does not sell medicines at all. The Office for Life Sciences' September 2026 statistics count 6,500 businesses in the UK life sciences sector in 2024/25, employing 306,700 people. Medical technology accounts for 59% of companies and biopharmaceuticals for 41%, and 25% of life sciences companies report manufacturing as their primary activity, with 19% reporting research and development. Employment is concentrated in the South East (25%), the East of England (15%) and London (13%), the regions around Oxford, Cambridge and London. None of this needs an agency on the doorstep: we run pharmaceutical research website design projects with teams across the UK.

That shifts the design priorities substantially. Pipeline and platform pages replace product pages. Publication lists, trial registrations, and named scientific leadership do the work that customer testimonials do elsewhere. Investor relations content needs its own governance, since it carries disclosure obligations that have nothing to do with the MHRA. And recruitment matters far more than it does for a commercial pharma site, because the scarce resource is scientists rather than customers.

Two groups need their own brief. Contract development and manufacturing organisations sell capacity, quality systems and technical capability to other companies, so they have more in common with industrial B2B buyers than with prescribers, and the patterns in our guide to web design for manufacturers apply: capability pages, certifications and a fast route to a technical conversation. Medical device companies work under a separate rulebook again, the UK medical devices regulations, so do not assume a medicines template carries over.

The regulatory load is lighter, but the content burden is heavier. A pharmaceutical research website that looks like a generic B2B site will underperform, because the audience is unusually good at detecting imprecision. Specificity is the conversion mechanism: name the modality, name the target, name the phase, cite the paper. Vagueness reads as weakness to this audience in a way it does not elsewhere.

Designing for Patients, Prescribers and Investors

Three audiences, three genuinely different information needs, and one site. This is the core UX problem.

Patients and carers arrive worried and often on a phone. They need plain-English answers, realistic expectations, and an obvious route to the information their clinician will want them to have. Reading age matters: aim for accessible language without being patronising, and put the summary before the detail rather than after it.

Prescribers and pharmacists arrive sceptical and time-poor. They want the data, the references, the dosing, and the safety profile, and they want it in two clicks. Nothing damages credibility faster with this group than making them scroll past patient-facing reassurance to reach the evidence.

Investors and partners want pipeline, milestones, regulatory status, and leadership. They will read your news section chronologically and notice gaps.

The mistake is trying to serve all three from a shared homepage. The better pattern is a clear, early fork, with each path fully self-contained afterwards, and no cross-contamination of tone between them. The same logic applies in other regulated sectors: our guides to medical website design and web design for financial advisers cover the same audience-splitting problem under different rulebooks.

Common UX Problems in Pharma and HCP Portals

Pharmaceutical sites fail their users in a small number of repeatable ways, and almost all of them come from compliance decisions taken without a UX counterweight. These are the issues we find most often when auditing an existing pharma or HCP portal.

• The gate asks for more than it needs. A self-certification interstitial only has to establish that the visitor is a UK healthcare professional. When it is expanded into a full registration form with specialty, GMC number and a password, the drop-off is severe and the extra data is rarely used. Gate first, register later, and only where the content genuinely requires it.
• Prescribing information is buried. It has to be present and prominent, but it is often reduced to a footer link on page 12. Put a persistent, clearly labelled route to prescribing information and safety data on every promotional HCP page.
• Everything is a PDF. Summaries of product characteristics, patient leaflets, dosing guides and slide decks dumped as PDFs are hard to read on a phone, invisible to assistive technology if scanned, and effectively unsearchable. Publish the HTML version first and offer the PDF as the download.
• Site search does not understand clinical vocabulary. Prescribers search by molecule, brand, indication and abbreviation interchangeably. A search index that only matches page titles will return nothing for two of those four, and the user assumes the content does not exist.
• Session timeouts discard work. Security policies on HCP portals often log users out aggressively. If that happens mid-form on an adverse event report or an unfilled sample request, the content is lost and frequently not re-entered.
• Dosing tables break on mobile. A wide clinical table that requires horizontal scrolling on a phone is the single most common accessibility and usability failure on HCP content, and a substantial share of prescriber traffic is mobile.
• The patient route and the HCP route look identical. If both sides share a template and a tone, users lose track of which section they are in, which is a compliance risk as well as a usability one. Signpost the context persistently, not just at the fork.

None of these require loosening a compliance position. They are all cases where the compliant option and the usable option were never properly reconciled, and a competent pharma web design process reconciles them at wireframe stage rather than at launch.

Accessibility Is a Legal Question, Not a Design Preference

There is persistent confusion about which accessibility law applies to whom, so to be precise about it. The Public Sector Bodies (Websites and Mobile Applications) Accessibility Regulations 2018 impose a WCAG-based duty on public sector organisations, which most pharmaceutical companies are not. However, the Equality Act 2010 requires service providers to make reasonable adjustments for disabled people, and that duty does apply to private companies including pharma.

In practice, the sensible target is the same either way: WCAG 2.2 at AA. It is the recognised benchmark, it is what a court or a complainant would reference, and it is what NHS and public sector partners will expect if you ever work with them. Treating it as optional on a site whose users disproportionately have disabilities is difficult to justify commercially, let alone ethically.

Inclusive Web Design for Pharma: Beyond the WCAG Checklist

Accessibility compliance and inclusive design are related but not the same. Compliance asks whether the page passes a standard. Inclusive design asks whether a real person, on a bad day, with the symptoms your product treats, can actually complete the task. In this sector the gap between the two is unusually wide, and it is where the practical work sits.

• Dosing tables and calculators must be usable with a screen reader, which means real table markup with scope attributes and associated labels, not a visual grid of divs that looks tidy and announces nothing.
• Adverse event forms must be completable by someone experiencing an adverse event. Tremor, blurred vision, nausea and cognitive fog are all plausible states for the person filling that form in. Large targets, forgiving validation, no time limits, and the ability to save and resume.
• Patient information leaflets published as scanned PDFs are invisible to assistive technology. Publish accessible HTML as the primary format and keep the PDF as a secondary download.
• Plain-English summaries are an accessibility feature, not a dumbing-down. Cognitive accessibility is part of WCAG, and a summary above the clinical detail serves anxious patients, carers and time-poor clinicians at the same time.
• Do not rely on colour alone to communicate risk or status. Warning states, contraindication flags and severity scales all need a text or shape cue alongside the colour.
• Test with people, not only with scanners. When the Government Digital Service tested 10 automated checkers in 2017 against a page built with 143 deliberate failures, no single tool found more than 41% of them, even counting manual inspection prompts, and 29% were missed by every tool. A short moderated session with a screen reader user finds the ones that matter. The W3C's introduction to web accessibility is a reasonable grounding for the team before that session happens.

Pharma Web Design or Pharma Web Development: What the Project Actually Needs

Companies searching for pharma web design services frequently need pharma web development, and the distinction is worth being clear about because it determines the budget, the team and the timeline.

Design work covers the visual system, the information architecture, the content model, and the compliance-aware component library. It is where the audience-splitting and the regulatory constraints get resolved on paper. Development work covers the parts that carry ongoing risk once the site is live.

A useful test: if your problem is that the site looks dated and does not explain the science well, it is a design project. If your problem is that updating a claim takes six weeks and three email chains, or that nobody can prove who approved what, it is a development and workflow project. Most pharmaceutical websites that frustrate their owners are failing on the second, and a redesign will not fix it.

What Website Development for Pharmaceutical Companies Covers

The engineering scope on a regulated build is wider than on a corporate site of the same page count, and the difference is almost entirely in governance rather than in visual complexity.

• Approval workflow in the CMS. Draft, medical review, regulatory review, approval, publication, expiry. Each state recorded with a user, a timestamp and a version. Clause 8.1 of the Code requires promotional material, including material on the internet, to be certified in its final form, and clause 8.6 requires the certified form to be preserved. So the CMS has to lock the certified version, treat any later edit as new material that needs certifying, and keep the old version retrievable. If this runs over email instead, you have no audit trail when you need one.
• A referenced content model. Claims are structured objects with a reference, an approver and a review date attached, not free text in a WYSIWYG field. That is what makes an annual re-approval cycle tractable instead of a manual page-by-page sweep.
• HCP gating logic. Server-side enforcement that covers files as well as pages, a sensible cookie duration, correct handling of deep links from email and search, and a gate that does not accidentally block your own analytics. HCP portal design succeeds or fails on this part, as the ruling below shows.
• Adverse event capture and routing. Validated form handling, encryption, a defined internal notification path with a response time, and a clear onward route to the MHRA Yellow Card scheme.
• Multi-market content governance. Where a product is approved in several markets, the site has to serve market-specific labelling without leaking one market's approved claims into another. That includes the UK itself: the MHRA says a medicine can only be advertised in a territory where it is licensed, so a UK-wide page needs the product covered by licences in Great Britain and in Northern Ireland, with both sets of licence details shown where they are separate.
• Integrations. Reference and asset management systems, CRM, consent management, and whatever holds the approved claim library. These are usually the long pole in the schedule.
• Content expiry and review automation. Approvals lapse. Under clause 8 of the Code, material still in use must be recertified at intervals of no more than two years, and clause 6.5 bars the word "new" for any product that has been generally available for more than twelve months in the UK. The system should surface both before a reviewer or a complainant does, ideally as a dashboard rather than a calendar reminder.

We handle both sides through web design and WordPress web development, and on regulated projects the workflow build is usually the larger half of the engagement.

What a 2025 PMCPA Ruling Shows About HCP Gates

The gap between a gate that looks right and one that works is not theoretical. In CASE/0395/12/24, completed in November 2025 under the 2024 Code, a complainant searched Google for the name of CSL Vifor's healthcare professional website and opened a patient leaflet for a prescription-only medicine without passing the site's self-certification pop-up. The company said the site was not intended to be reachable through search engines, and put it down to a technical issue with how two PDF files had been made non-indexable. The Panel ruled breaches of clause 26.1 (promoting a prescription-only medicine to the public) and clause 16.1, and said it was important that material intended for health professionals included a requirement to self-certify. The same case found a breach of clause 6.5, because a recording of a November 2022 presentation, still on the site in December 2024, described a medicine as "new" when it had been licensed since April 2022.

Three build lessons follow, and none of them is about the visual design:

• Enforce the gate on the server for every file, not just pages. A pop-up in the browser does nothing for a PDF opened from a search result or a forwarded email.
• Keep HCP assets out of search indexes as a second line of defence. Google's documentation says to use the X-Robots-Tag response header to block indexing of non-HTML files such as PDFs, because a robots meta tag cannot be placed inside them. It does not replace the gate, since anyone with the link can still open the file.
• Date archived recordings and decks prominently. Treat time-bound words such as "new" as content with an expiry date, and retire or edit the material before the date passes.

Choosing a Pharma Web Design and Development Agency in the UK

Most agencies will say yes to a pharmaceutical project. Fewer have built one that survived a code review. These are the questions that separate the two, and they are worth asking before the pitch rather than after the contract.

1. Ask how they handle claim referencing in the CMS. If the answer is "the client adds the reference in the text", they have not built a regulated site before.
2. Ask what happens when an approval expires. A good answer describes a system behaviour. A weak answer describes a person remembering.
3. Ask who signs off accessibility, and against what. "WCAG 2.2 AA, tested with a screen reader and documented" is the answer you want. "It is responsive" is not.
4. Ask how the HCP gate is enforced. Client-side only is a red flag, because the content is still fetchable. Ask specifically how PDFs and other files are protected, because an unprotected PDF was at the heart of the CSL Vifor ruling.
5. Ask how they keep HCP material out of search. If the answer is robots.txt, keep asking. Google's robots.txt documentation says it is not a mechanism for keeping a web page out of Google; noindex, an X-Robots-Tag header or access control does that job.
6. Ask about the handover. A regulated site your team cannot update without the agency is a compliance risk, because urgent safety updates do not wait for a support queue.
7. Ask what they maintain after launch. Security patching, dependency updates and accessibility regression testing on a regulated site are continuing obligations, not an optional retainer.

Sector-specific experience helps, but it is not the only signal. An agency with a strong track record in another heavily regulated sector, and an honest process for working with your medical and regulatory colleagues, will usually outperform one that has pharma logos on the wall and a purely visual process behind them.

What a Pharmaceutical Website Costs in the UK

There is no standard price, and anyone quoting one before they have seen your approval process is guessing. Our UK website cost guide puts full service agency builds at £5,000 to £20,000. Treat that band as the floor for a regulated build rather than the ceiling, because the approval workflow, server-side gating, adverse event routing and integrations are exactly what a template build leaves out. Running costs need the same honesty: in our website maintenance cost guide, sites with forms and integrations sit in the £150 to £400 a month band, before any time spent on recertification changes. Every Peak Digital project starts with a free scoping call and a fixed-price quote within 48 hours, so the budget is agreed before any code is written.

Pharmaceutical Website Examples: What to Look For

Search for examples of pharmaceutical websites and you mostly get inspiration galleries and "best of" lists. They are useful for visual direction, but a screenshot cannot show the parts that decide whether a site survives a complaint. When you benchmark your own site or anyone else's, test these instead:

• Where the audience fork sits. A strong site splits patients and professionals before any product name appears, and keeps telling you which side you are on.
• Whether the gate covers documents. Search for one of your HCP PDFs by name and check whether it opens without the self-certification step.
• How far prescribing information is from a claim. On promotional HCP pages it should be one obvious click away, not in the footer.
• Whether references are dated and attached to the claim they support. A single reference list at the bottom of a long page is the weakest version.
• Whether reference information is readable HTML. The summary of product characteristics and the leaflet as pages, with the PDF as a download, is the accessible pattern.
• How the side effect reporting route is signposted. It should be visible on every relevant page and work on a phone.

An example that passes all six is worth more than ten that look good in a gallery.

A Practical Build and Maintenance Checklist

1. Confirm which site type you are building: POM, OTC, unbranded awareness, or corporate and research.
2. Map audiences to site sections and define the gating rule for each before wireframing.
3. Serve HCP-only files from behind the gate, send an X-Robots-Tag noindex header with them, and test by opening each one from a private browser window. Our technical SEO checklist covers how to check what Google has already indexed.
4. Build a content model where every claim has a reference field, an approver, and a review date.
5. Agree the sign-off workflow with medical and regulatory colleagues, and build it into the CMS rather than running it over email.
6. Set WCAG 2.2 AA as the acceptance criterion and test with a screen reader, not only an automated scanner.
7. Implement adverse event reporting with a clear route to the MHRA Yellow Card scheme and an internal notification path with a defined response time.
8. Run a UK GDPR review covering special category data, retention, and your data protection impact assessment.
9. Schedule recertification by expiry date (material still in use has to be recertified at least every two years under the Code), so approvals lapse visibly rather than silently.
10. Structure the site for search: descriptive headings, clean URLs, and schema markup that does not overstate claims. Our SEO team works within the same constraints rather than around them.
11. Plan the maintenance budget alongside the build budget. Regulated sites decay faster because their content has a shelf life, and security patching on a site that holds special category data is not optional. Our website maintenance packages cover that side.
12. If you are replacing an existing site, map every indexed URL to its new home and redirect it before launch, as our website migration SEO guide sets out, so the rebuild does not cost you the search visibility the old site had.

If the promotional side is also in scope, our companion guide to digital marketing for pharmaceutical companies covers the channel-level rules, and dental web design covers a lighter-touch regulated healthcare build if that is closer to your situation.

Frequently Asked Questions